Prestige Consumer Healthcare PBH Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| International OTC Healthcare | $175.13M-1.5% | $175.63M-0.2% | $179.26M+4.9% | $179.88M+6.6% | $177.75M+6.4% | |
| North American OTC Healthcare | $913.58M-4.8% | $927.98M-1.5% | $931.22M-0.9% | $940.27M-0.4% | $960.01M+0.2% | |
| Gross Profit by Business | ||||||
| International OTC Healthcare | $94.7M-8.3% | $98.3M-2.9% | $101.81M+3.4% | $103.99M+8.1% | $103.32M+8.1% | |
| North American OTC Healthcare | $500.88M-5.7% | $520.99M+1.2% | $521.16M+1.3% | $524.78M+1.0% | $531.14M+0.4% | |
| Contribution Margin by Business | ||||||
| International OTC Healthcare | $66.77M-13.3% | $71.07M-5.8% | $75M+1.2% | $77.33M+5.1% | $77.03M+4.5% | |
| North American OTC Healthcare | $380.03M-5.4% | $397.52M+3.4% | $399.39M+4.7% | $400.15M+3.7% | $401.71M+1.1% | |
| Goodwill, Gross by Business | ||||||
| International OTC Healthcare | $125M+1.7% | $123.36M+0.1% | $121.97M-1.5% | $122.79M+1.0% | $122.92M+2.0% | |
| North American OTC Healthcare | $2.95B+3.7% | $2.9B+1.8% | $2.85B0.0% | $2.85B0.0% | $2.85B0.0% | |
| Cost of Sales by Business | ||||||
| International OTC Healthcare | $80.43M+8.1% | $77.33M+3.3% | $77.45M+7.1% | $75.89M+4.6% | $74.43M+4.0% | |
| North American OTC Healthcare | $412.7M-3.8% | $406.99M-4.7% | $410.06M-3.6% | $415.49M-2.2% | $428.87M-0.1% | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | ||||||
| International OTC Healthcare | $6.35M0.0% | $6.35M0.0% | $6.35M0.0% | $6.35M0.0% | $6.35M0.0% | |
| North American OTC Healthcare | $850.06M0.0% | $850.06M0.0% | $850.06M0.0% | $850.06M0.0% | $850.06M0.0% | |
| Advertising and marketing by Business | ||||||
| International OTC Healthcare | $27.94M+6.2% | $27.23M+5.5% | $26.81M+9.8% | $26.66M+18.0% | $26.29M+20.5% | |
| North American OTC Healthcare | $120.85M-6.6% | $123.47M-5.3% | $121.78M-8.7% | $124.63M-6.9% | $129.43M-1.6% | |
| Effects of foreign currency exchange rates by Business | ||||||
| International OTC Healthcare | $1.63M— | —— | —— | —— | —— | |
| North American OTC Healthcare | -$721K— | $0— | $0— | $0— | $0— | |
| Goodwill by Business | ||||||
| International OTC Healthcare | $118.65M+1.8% | $117.02M+0.1% | $115.63M-1.6% | $116.44M+1.1% | $116.57M+2.1% | |
| North American OTC Healthcare | $2.1B+5.2% | $2.05B+2.6% | $2B0.0% | $2B0.0% | $2B0.0% | |
| Total revenues by Product | ||||||
| Analgesics | $113.94M-3.2% | $115.9M+0.5% | $118.85M+3.7% | $118.34M+0.5% | $117.7M+0.2% | |
| Cough & Cold | $101.91M-4.1% | $102.53M-2.8% | $102.53M-6.2% | $104.52M-7.7% | $106.21M-10.8% | |
| Dermatologicals | $125.93M-2.3% | $124.53M-4.7% | $125.54M-1.8% | $125.7M-0.6% | $128.95M-0.1% | |
| Eye & Ear Care | $142.94M-22.0% | $151.81M-15.9% | $158.89M-11.7% | $167.5M-9.0% | $183.32M+2.2% | |
| Gastrointestinal | $259.79M+1.5% | $260.32M+5.5% | $259.85M+8.6% | $255.71M+10.2% | $255.94M+10.5% | |
| Oral Care | $101.05M+6.3% | $100.15M+7.4% | $96.64M+3.2% | $95.96M+3.9% | $95.03M-1.3% | |
| Other OTC | $15.39M+11.7% | $13.88M+6.8% | $13.31M+5.4% | $13.41M+9.7% | $13.78M+14.6% | |
| Women's Health | $227.77M-3.8% | $234.5M+0.5% | $234.86M+0.6% | $239.01M+1.7% | $236.83M-1.5% | |
| Concentration risk, percentage by Product | ||||||
| Manufacturers | 60%+2.0pp | 59.5%-2.0pp | 59%-6.0pp | 58.5%-10.0pp | 58%-14.0pp | |
| Manufacturers, United States, Canada and Australia | 21%— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Prestige Consumer Healthcare break its business down?
- Prestige Consumer Healthcare (PBH) reports total revenues by business across 2 parts — International OTC Healthcare and North American OTC Healthcare. Each is extracted from the segment footnotes and tracked over time.
- Where does Prestige Consumer Healthcare's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Prestige Consumer Healthcare's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.